LY392098

LY392098 is a synthetic small molecule belonging to the biarylpropylsulfonamide class that acts as a highly potent and selective *positive allosteric modulator* of the **AMPA receptor** (glutamate receptor ionotropic AMPA)[1][3][5][7][8][10]. It potentiates AMPA receptor-mediated currents in neurons, enhancing glutamatergic neurotransmission in a concentration- and activity-dependent manner, but has no effect on NMDA receptors[1][3][10]. LY392098's antidepressant-like effects are demonstrated in animal models (e.g., forced swim and tail suspension tests), likely via its action on synaptic plasticity and BDNF expression in cortical neurons[2][3][5][6]. The drug was originally developed by **Eli Lilly** for the potential treatment of neuropsychiatric disorders, such as depressive disorder and major depression, but remains at a *preclinical development stage*[5][6].

Other names

LY392098LY-392098LY 392098